UNASSIGNED: Currently, there is no characteristic microRNA (miRNA) expression pattern in @entity9653 + diffuse large @entity1892 of the elderly (EBV+DLBCLe). This study aims to characterize a signature profile and identify miRNAs that can be used as biomarkers and alternative therapeutic targets for EBV+DLBCLe. Seventy-one DLBCL @entity1 aged 50 years and older were included and four EBV+ and four EBV- samples were analyzed in two miRNA array platforms (pilot study). A larger multicenter cohort (29 EBV+DLBCLe and 65 EBV-DLBCL @entity1 ) was used to validate the results by real-time polymerase chain reaction. In the pilot study, 9% of DLBCL were EBV+DLBCLe by in situ hybridization. In multicenter study, EBV+DLBCLe group showed a predominance of non-germinal center B-cell origin. Overall survival duration of EBV+DLBCLe was significantly inferior to that of EBV-DLBCL @entity1 . We found 10 deregulated miRNAs in the two groups, but only seven were statistically different. We confirmed overexpression of @entity10013 , hsa-miR-146a, hsa-miR-146b, @entity6529 , and @entity10074 and underexpression of @entity40548 in EBV+DLBCLe cases compared to EBV-DLBCL cases. Hsa-miR-146b and @entity10074 showed high specificity for identifying EBV+DLBCLe. The present study proposed a miRNA signature for EBV+DLBCLe and our findings suggest that hsa-miR-146b and @entity10074 could be biomarkers and therapeutic targets.

A microRNA signature profile in EBV+ diffuse large XXXX of the elderly.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma'] @entity9653 :: ('10376', 'Species') :: ['Epstein-Barr virus'] @entity10013 :: ('406913', 'Gene') :: ['hsa-miR-126'] @entity40548 :: ('442893', 'Gene') :: ['hsa-miR-151'] @entity10074 :: ('407007', 'Gene') :: ['hsa-miR-222'] @entity6529 :: ('406942', 'Gene') :: ['hsa-miR-150']
@entity1892 :: (MESH:D016393,Disease) :: ['B-cell lymphoma']
